 Late cardiac effects doxorubicin therapy acute lymphoblastic leukemia childhood BACKGROUND Cardiotoxicity recognized complication doxorubicin therapy long-term effects doxorubicin cardiac status children acute lymphoblastic leukemia doxorubicin years disease continuous remission METHODS Eighteen patients dose doxorubicin mg square meter body-surface area multiple doses mg square meter median median interval end treatment cardiac evaluation years evaluation history ambulatory electrocardiographic recording exercise testing echocardiography RESULTS Fifty-seven percent patients abnormalities left ventricular afterload end-systolic wall stress contractility stress-velocity index cumulative dose doxorubicin significant predictor abnormal cardiac function Seventeen percent patients dose doxorubicin age-adjusted afterload none contractility contrast percent patients mg doxorubicin square meter afterload percent patients contractility percent afterload due ventricular wall thickness hypertension ventricular dilatation multivariate analyses patients mg doxorubicin square meter significant predictive factors cumulative dose decreased contractility age years treatment afterload Afterload patients percent symptoms indexes exercise tolerance ventricular function Eleven patients congestive heart failure year treatment doxorubicin recurrent heart failure years doxorubicin treatment required heart transplantation patient late heart failure new event CONCLUSIONS Doxorubicin therapy childhood impairs myocardial growth dose-related fashion results progressive increase left ventricular afterload reduced contractility loss myocytes doxorubicin therapy childhood inadequate ventricular mass important heart disease later years